Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.29M 3.95M 3.7M 6.94M 463M 7.05M 47.48M 18.38M 227M 18.34M 17.94M 789M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.24M 10.36M 9.7M 18.17M 1.21B 18.48M 124M 48.15M 595M 48.04M 47.01M 2.07B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Aradigm Corporation Stock

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
LONZA GROUP AG	+2.91%	+7.89%	-6.63%	+1.99%	44.45B
REVOLUTION MEDICINES, INC.	-1.10%	+6.79%	+320.91%	+577.48%	36.04B
BEONE MEDICINES AG	+1.57%	+6.88%	+5.23%	+55.90%	30.7B
IQVIA HOLDINGS INC.	+6.98%	+7.84%	+16.06%	-13.92%	28.59B
CELLTRION, INC.	-4.75%	-8.02%	+5.99%	+12.28%	23.01B
ASCENDIS PHARMA A/S	+0.42%	+3.81%	-	-	14.82B
MEDPACE HOLDINGS, INC.	+6.48%	+10.43%	+60.10%	+124.23%	13.52B
EUROFINS SCIENTIFIC SE	+2.73%	+7.20%	+11.00%	+19.38%	12.98B
IONIS PHARMACEUTICALS, INC.	+1.20%	+3.19%	+93.44%	+96.11%	12.56B
Average	+1.68%	+2.88%	+63.26%	+109.18%	21.67B
Weighted average by Cap.	+1.76%	+3.06%	+70.14%	+127.02%

	2016	2017
Net sales	195K 171K 158K 148K 277K 18.47M 282K 1.9M 734K 9.06M 732K 716K 31.5M	14.46M 12.71M 11.71M 10.96M 20.54M 1.37B 20.88M 141M 54.42M 672M 54.3M 53.13M 2.34B
Net income	-32.94M -28.94M -26.66M -24.96M -46.76M -3.12B -47.55M -320M -124M -1.53B -124M -121M -5.32B	-10.7M -9.4M -8.67M -8.11M -15.2M -1.01B -15.45M -104M -40.28M -498M -40.19M -39.32M -1.73B
Net Debt	-9.37M -8.23M -7.59M -7.1M -13.31M -888M -13.53M -91.09M -35.26M -436M -35.18M -34.43M -1.51B	7.91M 6.95M 6.41M 6M 11.23M 750M 11.42M 76.91M 29.77M 368M 29.71M 29.07M 1.28B